GSK Pursuing Late-Stage Inflammatory Bowel Disease Treatment With ChemoCentryx
This article was originally published in The Pink Sheet Daily
Executive Summary
Collaboration includes potential payments of up to $1.5 bil. for co-development rights to Traficet-EN and other chemokine and chemoattractant receptors.